According to Zacks, “Valneva SE is a specialty vaccine company. It is focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. Valneva SE is based in Saint-Herblain, France. “
Separately, UBS Group lowered Valneva from a “neutral” rating to a “sell” rating in a research note on Wednesday, December 22nd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $37.00.
A number of large investors have recently modified their holdings of VALN. Alps Advisors Inc. acquired a new stake in shares of Valneva in the 4th quarter valued at $3,369,000. Granite Point Capital Management L.P. acquired a new stake in shares of Valneva in the 3rd quarter valued at $376,000. Millennium Management LLC acquired a new stake in shares of Valneva in the 2nd quarter valued at $259,000. Finally, Morgan Stanley acquired a new stake in shares of Valneva in the 3rd quarter valued at $97,000. 0.50% of the stock is currently owned by institutional investors and hedge funds.
Valneva Company Profile (Get Rating)
Valneva SE, a specialty vaccine company, focused on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; and DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium.
- Get a free copy of the StockNews.com research report on Valneva (VALN)
- Greenbrier Companies Stock has Green in its Future
- Insiders Are Selling Palo Alto Networks
- Headwinds Mount For Carmax, Don’t Count On Higher Share Prices
- 3 Bank Stocks That Are Ready to Handle Whatever the Fed Throws at Them
- Tilray Stock Has Better Days Ahead
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Valneva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valneva and related companies with MarketBeat.com's FREE daily email newsletter.